Awakn Life Sciences Begins Trading on the OTCQB(R) Venture Market Under the Symbol ‘AWKNF’ on August 12th

Toronto, Ontario–(Newsfile Corp. – August 12, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (‘Awakn’), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, is pleased to announce that it has qualified to trade on the OTCQB® Venture Market (“OTCQB”) under the ticker symbol “AWKNF” today, Tuesday, August 12, 2021.

The OTCQB is the venture tier of OTC Markets on which 11,000 U.S. and global securities trade. Trading on the OTCQB will enhance the visibility and accessibility of the Company to U.S. investors. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

“The uplisting to the OTCQB is a significant achievement in our strategy to broaden our reach and access into the institutional and retail investment community in the United States. We look forward to introducing Awakn to both the U.S. institutional and retail investment community as we continue move forth our strategy of researching, developing and delivering psychedelic medicine to better treat Addiction,” said Anthony Tennyson, Awakn’s CEO.

The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities. OTC Markets Group enables investors to easily trade through the broker of their choice and empowers companies to improve the quality of information available for investors. OTCQB listed companies must be current in their financial reporting and undergo an annual verification and management certification process, including meeting a minimum bid price and other financial conditions. With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions.

About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

About OTC Markets Group Inc.
OTC Markets Group Inc. operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 11,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, PTC Market Group Inc. connects a diverse network of broker-dealers that provide liquidity and execution services. The company enables investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. To learn more about how OTC Markets Group Inc. creates better informed and more efficient markets, visit www.otcmarkets.com.

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC. 

OTC Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92844